

UVI 3003

Catalog No: tcsc0028638



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

847239-17-2

Formula:

$C_{28}H_{36}O_4$

Pathway:

Metabolic Enzyme/Protease

Target:

RAR/RXR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

436.58


Product Description

UVI 3003 is a highly selective antagonist of **retinoid X receptor (RXR)**, and inhibits xenopus and human **RXRα** in Cos7 cells, with **IC₅₀**

s of 0.22 and 0.24 μM , respectively.

IC50 & Target: IC50: 0.22 μM (Xenopus RXR α , in Cos7 cells), 0.24 μM (Human RXR α , in Cos7 cells)^[1]

In Vitro: UVI3003 inhibits the activity of xenopus and human RXR α , with IC₅₀s of 0.22 and 0.24 μM , respectively. UVI3003 fully activates xPPAR γ with an EC₅₀ of 12.6 μM , and is almost completely inactive on hPPAR γ and mPPAR γ ^[1]. UVI 3003 (10 μM) does not change the proliferation rate of extraocular muscles (EOM)-derived or LEG-derived EECD34 cells. UVI 3003 causes a 65.4% difference in EECD34 cell fusion and desmin expression^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!